Skip to main content

Table 5 Characteristics of the CNS lupus patients with large abnormal MRI signals

From: Diagnostic reliability of magnetic resonance imaging for central nervous system syndromes in systemic lupus erythematosus: a prospective cohort study

Case Duration of SLE (yrs) SLEDAI SLEDAI without CNS aPL* SLE-related CNS syndrome Treatment Clinical outcome of CNS lupus MRI change
1 0 31 15 Positive Seizure disorder, Headache Steroids Improve Improve
2 0 11 3 Negative Acute confusional state Steroids + CPA Improve Improve
3 1 24 8 Negative Demyelinating syndrome, Acute confusional state Steroids + CPA Improve Improve
4 9 29 5 Positive Demyelinating syndrome, Seizure disorder, Acute confusional state Steroids + CPA Improve Improve
5 4 16 0 Negative Demyelinating syndrome, Acute confusional state Steroids + CPA No change No change
6 8 10 2 Negative Cerebrovascular disease Steroids + CPA + anticoagulant No change No change
7 5 22 6 Negative Acute confusional state Steroids + CPA No change Deteriorate
  1. CNS: central nervous system; MRI: magnetic resonance imaging; SLE: systemic lupus erythematosus; SLEDAI: systemic lupus erythematosus disease activity index; aPL: antiphospholipid antibody; CPA: cyclophosphamide.
  2. *aPL includes lupus anticoagulant, anti-cardiolipin antibodies, and anti-β2GPI antibodies.
  3. †The case numbers given are not identifying numbers.